Search clinical trials for: MK-8777

Total 1765 results

Merck Sharp & Dohme LLC
Eisai Inc.

Active, not recruiting

A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)

Carcinoma, Renal Cell

Canada, United States, Argentina, Australia, Austria, Belgium, Brazil, Chile, Colombia, Czechia, Finland, France, Germany, Greece, Ireland, Italy, Japan, Korea, Republic of, Netherlands, Poland, Romania, Russian Federation, Spain, Swi... and more
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate and Compare the Efficacy and Pharmacokinetics of MK-0873 for the Treatment of Plaque Psoriasis (MK-0873-022)

Psoriasis | Plaque Psoriasis

United States
Merck Sharp & Dohme LLC

Terminated

A Study of MK-6913 for the Treatment of Hot Flashes in Postmenopausal Women (6913-004)

Women | Moderate to Severe Vasomotor Symptoms in Postmenopausal
Merck Sharp & Dohme LLC

Active, not recruiting

Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99)

Small Cell Lung Cancer

Poland, Russian Federation, United States, Austria, Canada, Hungary, Israel, Italy, Korea, Republic of, Spain, Switzerland
Merck Sharp & Dohme LLC
Eisai Inc.

Completed

Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) (MK-7902-007/E7080-G000-314/LEAP-007)

Non-small Cell Lung Cancer

China, Israel, United States, Australia, Canada, Colombia, Estonia, France, Hungary, Italy, Japan, Korea, Republic of, Malaysia, Mexico, Poland, Russian Federation, Taiwan, Turkey, Ukraine
Merck Sharp & Dohme LLC

Not yet recruiting

A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

Crohn's Disease
Merck Sharp & Dohme LLC
PPD, Part of Thermo Fisher Scientific

Recruiting

A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)

Ulcerative Colitis

United States, Israel, Japan, Korea, Republic of, Switzerland, Chile, Dominican Republic, Canada, Netherlands
Merck Sharp & Dohme LLC

Completed

A Study of Belzutifan (MK-6482) in Participants With Renal Impairment (MK-6482-021)

End Stage Renal Disease | Renal Impairment

United States
Merck Sharp & Dohme LLC

Completed

Study of MK-4482 for Prevention of Coronavirus Disease 2019 (COVID-19) in Adults (MK-4482-013) (MOVe-AHEAD)

Coronavirus Disease (COVID-19)

United States, Argentina, Brazil, Bulgaria, Colombia, Dominican Republic, Egypt, France, Guatemala, Hungary, Japan, Kenya, Malaysia, Mexico, Peru, Philippines, Romania, Russian Federation, South Africa, Spain, Thailand, Turkey, Ukraine
Samsung Medical Center

Completed

Study of Pembrolizumab in Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-Line Therapy With Platinum and Fluoropyrimidine: Integration of Molecular Subtypes Through Integrative Genomic Analysis

Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

Korea, Republic of
Merck Sharp & Dohme LLC

Completed

Efficacy and Safety Study of Pembrolizumab (MK-3475) in Participants With Advanced Recurrent Ovarian Cancer (MK-3475-100/KEYNOTE-100)

Ovarian Neoplasms
Affimed GmbH
Merck Sharp & Dohme LLC; The Leukemia and Lymphoma Society

Completed

Study of the Combination of AFM13 and Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

Hodgkin Lymphoma

United States, Spain
Merck Sharp & Dohme LLC
Eisai Inc.

Active, not recruiting

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)

Glioblastoma | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Advanced Solid Tumors | Triple Negative Breast Cancer | Biliary Tract Cancers

United States, Argentina, Australia, Canada, Chile, Colombia, France, Germany, Israel, Italy, Korea, Republic of, Russian Federation, Spain, Switzerland, Taiwan, Thailand, United Kingdom
Merck Sharp & Dohme LLC
Eisai Inc.

Active, not recruiting

Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61) (KEYNOTE-B61)

Renal Cell Carcinoma

Poland, Australia, United States, Canada, France, Hungary, Ireland, Italy, Korea, Republic of, Russian Federation, Spain, Turkey, Ukraine, United Kingdom
Merck Sharp & Dohme LLC

Active, not recruiting

Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007)

Solid Tumors

Poland, Korea, Republic of, United States, Argentina, Australia, Canada, Colombia, France, Germany, Guatemala, Israel, Italy, Japan, Latvia, Mexico, Peru, Puerto Rico, Romania, South Africa, Spain, Sweden, Turkey, Ukraine
King's College London
Washington Red Raspberries Commission

Recruiting

Gut Microbial Metabolism of Polyphenols and Cardiovascular Health (StratiPol) (Stratification Study) (StratiPol)

Healthy

United Kingdom
Merck Sharp & Dohme LLC

Active, not recruiting

Clesrovimab (MK-1654) in Infants and Children at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease (MK-1654-007)

RSV Infection

United States, Australia, Canada, Chile, Colombia, Czechia, Finland, France, Germany, Greece, Hong Kong, Hungary, Italy, Japan, Malaysia, Mexico, New Zealand, Norway, Peru, Puerto Rico, Singapore, South Africa, Spain, Taiwan, Thailand, Tu... and more
Sidney Kimmel Comprehensive Cancer Center at Johns...
Merck Sharp & Dohme LLC

Completed

Study of Azacitidine in Combination With Pembrolizumab in R/R AML Patients and in Newly Diagnosed Older Patients

Acute Myeloid Leukemia

United States
Lupin Research Inc

Completed

Evaluate the Safety of a Single Oral Dose of Solosec™ (Secnidazole) 2g for the Treatment of Adolescent Girls With BV

Bacterial Vaginoses

United States
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) Monotherapy for Metastatic Triple-Negative Breast Cancer (MK-3475-086/KEYNOTE-086)

Breast Cancer
Novartis Pharmaceuticals
Merck Sharp & Dohme LLC

Completed

Safety and Efficacy Study of Pazopanib and MK 3475 in Advanced Renal Cell Carcinoma (RCC; KEYNOTE-018)

Carcinoma, Renal Cell

United States, United Kingdom
Pfizer
Merck Sharp & Dohme LLC

Completed

A Study Of 4-1BB Agonist PF-05082566 Plus PD-1 Inhibitor MK-3475 In Patients With Solid Tumors (B1641003/KEYNOTE-0036)

Advanced Solid Tumors

United States
Merck Sharp & Dohme LLC

Terminated

Study of Preladenant for the Treatment of Antipsychotic Induced Movement Disorders in Participants With Schizophrenia (Study P04628)

Parkinsonian Disorders | Dyskinesia, Drug-Induced | Akathisia, Drug-Induced
Merck Sharp & Dohme LLC

Completed

A Study to Assess the Safety, Tolerability, and Effects of MK-0974 (Telcagepant) on Exercise Tolerance in Patients With Stable Angina (MK-0974-014)

Angina Pectoris | Coronary Heart Disease | Calcitonin Gene-related Peptide Receptor
Merck Sharp & Dohme LLC

Not yet recruiting

Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

NSCLC | Non-small Cell Lung Cancer
Organon and Co

Completed

A Long-term Safety and Tolerability Study of Ezetimibe Plus Atorvastatin in Participants With Coronary Heart Disease, Multiple Risk Factors, or Hypercholesterolemia Not Controlled by Atorvastatin (P01418/MK-0653-032)

Hypercholesterolemia
Jazz Pharmaceuticals

Recruiting

A Study of Suvecaltamide in Adults With Moderate to Severe Residual Tremor in Parkinson's Disease

Parkinson Disease | Tremor

United States, Spain, Germany, Poland
Institute of Cancer Research, United Kingdom
Merck Sharp & Dohme LLC

Recruiting

Trial of Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (PERSEUS1)

Castration-resistant Prostate Cancer

United Kingdom
Organon and Co

Completed

Efficacy and Safety of Corifollitropin Alfa (MK-8962) in Combination With Human Chorionic Gonadotropin (hCG) in Adolescent Males With Hypogonadotropic Hypogonadism (HH) (MK-8962-043)

Hypogonadotropic Hypogonadism

Brazil, Denmark, Italy, Mexico, Russian Federation, South Africa
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) Monotherapy in Locally Advanced/Metastatic Renal Cell Carcinoma (MK-3475-427/KEYNOTE-427)

Renal Cell Carcinoma
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)(MK-3475-199/KEYNOTE-199)

Metastatic Castration-resistant Prostate Cancer
Hoosier Cancer Research Network
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab in Combination With Chemotherapy for Patients With Advanced Colorectal Cancer

Colorectal Cancer

United States
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001/KEYNOTE-001) (KEYNOTE-001)

Cancer, Solid Tumor
Aduro Biotech, Inc.
Merck Sharp & Dohme LLC

Terminated

Safety and Efficacy of CRS-207 With Pembrolizumab in Gastric, Gastroesophageal Junction or Esophageal Cancers

Gastric Adenocarcinoma | Esophageal Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

United States
Merck Sharp & Dohme LLC

Completed

A Bridging Trial Comparing Sugammadex (Org 25969) at 1-2 Post-Tetanic Count (PTC) in Caucasian Participants. Part B (P05974)

Anesthesia, General
Shaheen Alanee
Merck Sharp & Dohme LLC

Unknown

Pembrolizumab in Combination With BCG After Ablation in Patients With UUTTCC Without Nephroureterectomy

Endoscopic Surgical Procedure | High Risk Superficial Upper Urinary Tract Transitional Cell Carcinoma | Transitional Epithelial Cells

United States
Merck Sharp & Dohme LLC
Eisai Inc.

Active, not recruiting

Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)

Malignant Melanoma

United States, Australia, Austria, Brazil, Canada, Chile, China, France, Germany, Israel, Italy, Korea, Republic of, Poland, South Africa, Spain, Sweden, Switzerland, United Kingdom
Merck Sharp & Dohme LLC
Eisai Inc.

Active, not recruiting

Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)

Urothelial Carcinoma

Hungary, United States, Argentina, Australia, Canada, China, Denmark, France, Germany, Israel, Italy, Japan, Korea, Republic of, Netherlands, Poland, Russian Federation, Spain, Taiwan, Turkey, United Kingdom
Merck Sharp & Dohme LLC

Completed

An Efficacy and Safety Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in the Treatment of Chronic Hepatitis C Virus (HCV) Genotype (GT)1, 4, or 6 Infection in Treatment-Naïve Participants Who Are on Opiate Substitution Therapy (MK-5172-062) (C-EDGE CO-STAR)

Chronic Hepatitis C
Merck Sharp & Dohme LLC

Recruiting

Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)

Solid Tumor | Endometrial Cancer | Cutaneous Squamous Cell Carcinoma

Canada, Australia, Taiwan, Malaysia, United States, Netherlands, Turkey, France
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate Next Day Effects of MK-4305 on Driving Performance (MK-4305-035 AM1)

Insomnia

Netherlands
Peloton Therapeutics, Inc., a subsidiary of Merck...

Active, not recruiting

A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004)

VHL - Von Hippel-Lindau Syndrome | VHL Gene Mutation | VHL Syndrome | VHL Gene Inactivation | VHL-Associated Renal Cell Carcinoma | VHL-Associated Clear Cell Renal Cell Carcinoma

United States, Denmark, United Kingdom, France
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-052)

Urothelial Cancer
Merck Sharp & Dohme LLC

Completed

Study of MK-3475 (Pembrolizumab) in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy (MK-3475-055/KEYNOTE-055)

Head and Neck Squamous Cell Carcinoma
Eli Lilly and Company

Completed

A Study of LY3819253 (LY-CoV555) in Healthy Participants

Healthy

United States
Incyte Corporation
Merck Sharp & Dohme LLC

Completed

Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carcinoma

UC (Urothelial Cancer)

United States, Spain, Hungary, Israel, United Kingdom, Korea, Republic of, Taiwan, Denmark, France, Netherlands, Italy, Canada, Japan, Turkey, Germany, Ireland, Australia, Russian Federation
Yale University

Completed

MK-3475 in Melanoma and NSCLC Patients With Brain Metastases

Melanoma | Non-Small Cell Lung Cancer | Brain Metastases

United States
Merck Sharp & Dohme LLC

Terminated

Immunologic Determinants of Response to Pembrolizumab (MK-3475) in Advanced Melanoma (MK-3475-161/KEYNOTE-161)

Advanced Melanoma

United States
Georgetown University
Merck Sharp & Dohme LLC; Incyte Corporation

Unknown

Pembrolizumab and Epacadostat in Patients With Thymic Carcinoma

Thymic Carcinoma | Thymus Neoplasms | Thymus Cancer

United States
Merck Sharp & Dohme LLC
Eisai Inc.

Completed

Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) [MK-7902-007/E7080-G000-314/LEAP-007] - China Extension Study (LEAP-007)

Non-small Cell Lung Cancer

China

Search clinical trials for: MK-8777

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Guatemala

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations